Is Juvederm safe with cirrhosis?

Juvederm (hyaluronic acid filler) is generally considered safe for use in patients with compensated cirrhosis and normal or improving liver function, provided there are no other contraindications such as active infection, coagulopathy, or severe immunosuppression. There is no evidence that hyaluronic acid fillers like Juvederm are hepatotoxic or that they worsen liver function in patients with stable, compensated liver disease.

Hyaluronic acid fillers are not metabolized by the liver and are broken down by local tissue enzymes, so systemic effects on liver function are not expected.

The main risks with dermal fillers are local complications (e.g., infection, vascular occlusion, granuloma), not systemic toxicity.

According to published reviews, patient factors such as cirrhosis do not inherently increase the risk of filler complications, as long as the patient is otherwise stable and not immunocompromised or coagulopathic.

There is no specific mention in the literature of increased adverse events or contraindications for hyaluronic acid fillers in patients with compensated cirrhosis.

Key considerations before proceeding:
Ensure platelet count and coagulation parameters are within normal limits, as cirrhosis can increase bleeding risk.
Avoid injections if there is active infection or significant immunosuppression.
Use aseptic technique to minimize infection risk, as cirrhosis can impair immune response.


In summary, Juvederm (hyaluronic acid) injections are considered safe in patients with compensated cirrhosis and stable labs, with no evidence of increased risk of liver-related complications. Standard precautions for dermal fillers apply.